Sten Verland, PhD MSc
Sten Verland is General Partner in the Life Science group and one of the three co-founders. Sten has a particular focus on investment opportunities related to immuno-oncology, autoimmune diseases, orphan diseases and infectious diseases.
During his career, Sten has been active as a serial entrepreneur and business angel and has co-founded ten start-ups, primarily in the biotech and CRO fields. While at Sunstone, Sten has played a key role in executing three M&A exits (Rigontec, Action Pharma and Zymenex) and one IPO (Orphazyme).
Sten holds a Master’s degree in Biology and Mathematics and a PhD in Immunology – both from the University of Copenhagen. Sten serves as a board member of the Danish Venture Capital and Private Equity Association (DVCA). In his spare time, Sten is both a keen yachtsman and a big admirer of classical music.